# Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery

> **NCT01207726** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 13 (actual)

## Conditions studied

- Stage IA Non-Small Cell Lung Carcinoma
- Stage IB Non-Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Entinostat
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01207726
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Slow Accrual due to patients not wanting daily clinic administration of 5AZA and/or 6 months of treatment after surgery.
- **Last updated:** 2019-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01207726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01207726, "Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT01207726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*